Use of different options of anti-inflammatory therapy in patients with severe COVID-19

The aim of the study. To compare effectiveness methylprednisolone, dexamethasone and tocilizumab in patients with severe coronavirus disease. Identify most appropriate treatment option.
 Materials methods. Patients group 1 (n=20) received for anti-inflammatory purposes at a dose 600–800 mg. 2 (n=82) pulse therapy methylprednisolone. 3 6 mg / day. Data are presented as M [25–75]. Statistical analysis results was performed using program "Statistica 10". Significance differences indicators assessed nonparametric Wilcoxon test. were considered reliable values p <0.05.
 Results. course disease development cytokine storm respiratory distress syndrome is characterized by an increase markers inflammation: median CRP 89.2 g l, – 64.2 76.2 did not differ significantly between groups (p> 0.05). level IL-6 61.8 pg ml, 64.6 46.5 ml without significant ferritin all exceeded normal values.
 Conclusions favourable result obtained when methylprednisolone: it possible to reduce mortality rate 59.8 %. relative risk developing VTE higher (RR12 6.8 [2.7–16.8] p12 <0.0001, RR23 0.15 [0.06–0.35] p23 <0.0001), which gives grounds confirm presence anticoagulant activity methylprednisolone